Actively Recruiting
Prospective Study on Endometrial Immune Profile Changes After Autologous Intrauterine Platelet Rich Plasma (PRP) Treatment
Led by Nadezhda Women's Health Hospital · Updated on 2026-04-17
50
Participants Needed
1
Research Sites
26 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating how autologous intrauterine platelet rich plasma (PRP) treatment affects the endometrial immune profile, endometrial thickness, hormone levels, and IVF outcomes in women undergoing assisted reproduction. The study focuses on women with infertility who have regular menstrual cycles and are receiving embryo transfers. It aims to understand how changes in immune cells within the endometrium may influence IVF success. Participants will receive PRP prepared from their own blood, which will be administered into the uterus by catheter shortly after the LH peak. The PRP administration involves a 1.5 ml dose delivered on day 2 after the LH peak, followed by a short recovery observation before discharge. This treatment is being evaluated for its effect on immune cell populations and hormone levels during the mid-luteal phase. During the study, researchers will measure endometrial immune cells (T cells, NK cells, macrophages) before and one month after PRP treatment. They will also assess endometrial thickness by ultrasound, blood levels of estradiol and progesterone, and track IVF outcomes including biochemical pregnancy up to 10 weeks and clinical pregnancy confirmed by ultrasound at 12 weeks. Participants will be monitored closely following treatment to evaluate these outcomes.
CONDITIONS
Brief Title
Endometrial Immune Profile Changes After Autologous Intrauterine PRP Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participating in Assisted Reproduction Treatment
- Having infertility
- Having regular menstrual cycles
- Embryo transfer of euploid embryos
You will not qualify if you...
- Uterine pathologies
- Endometrial Bacterial infections
- Active endometrial inflammation
- Polycystic ovary syndrome
- Cancer diagnostics
- Positive HIV, HCV or HBV tests
- Autoimmune diseases
- Recent immune therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Single day procedure with recovery
Participants receive autologous intrauterine platelet rich plasma (PRP) administered by catheter on day 2 after LH peak. After the procedure, participants are observed for 30 minutes and discharged home the same day.
1 visit (in-person)
Duration - Up to 12 weeks after treatment
Participants are monitored for changes in endometrial immune profile, endometrial thickness, and hormone levels, as well as for pregnancy outcomes following embryo transfer after PRP administration.
Visits up to 12 weeks for outcome assessments
Trial Site Locations
Total: 1 location
1
Nadezhda Women's Health Hospital
Sofia, Sofia, Bulgaria, 1330
Actively Recruiting
Research Team
G
Georgi Stamenov, MD
D
Dimitar Parvanov, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here